Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
Edgewise claims heart pressure reductions for Camzyos rival
Edgewise's hypertrophic cardiomyopathy asset saw “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves.
James Waldron
Apr 2, 2025 8:45am
BMS' MyoKardia scraps heart muscle pact with Fulcrum
Mar 5, 2025 5:30am
BridgeBio touts extension study data for ATTR-CM drug acoramidis
Nov 18, 2024 3:38pm
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
Edgewise unveils promising early data for heart disease drug
Sep 20, 2024 4:00am
BioMarin halts preclinical gene therapy for heart condition
Aug 6, 2024 9:01am
